- Home
- RRGB vs INKT Comparison
RRGB vs INKT Comparison
Compare RRGB & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRGB | INKT |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.1M | 53.1M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RRGB | INKT |
|---|---|---|
| Price | $3.50 | $13.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $9.50 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 319.6K | 50.8K |
| Earning Date | 05-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.43 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,315,014,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.46 | $6.66 |
| 52 Week High | $7.52 | $76.00 |
Technical Indicators
Market Signals| Indicator | RRGB | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 67.65 |
| Support Level | $3.20 | $13.43 |
| Resistance Level | $4.42 | $15.99 |
| Average True Range (ATR) | 0.23 | 1.08 |
| MACD | 0.08 | 0.30 |
| Stochastic Oscillator | 86.81 | 92.40 |
Price Performance
Historical ComparisonAbout RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. The company's brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. It has one operating and one reportable segment: restaurants.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.